to PD-1 blockade response, and the effects of treatment sequence, with potential immune-sculpting effects on subsequent therapies, are increasingly evident. Furthermore, numerous checkpointmolecule-targeting strategies, whether they be blockade of inhibitory molecules or activation of stimulatory ones, are in development; it remains unknown whether the lessons learned from detailed study of existing immune checkpoint blockade-treated patients will transfer to these newer agents. Finally, it is becoming increasingly apparent that factors outside of the tumor and microenvironment (such as the overall host immune status and the gut microbiome) may influence therapeutic responses, and these factors must be taken into consideration in a more holistic approach to cancer therapy. Nonetheless, significant gains are being made through such integrated approaches as those presented herein.
Innate lymphoid cells (ILCs) are tuned to quickly respond to and amplify tissue-specific signals. Work of three independent groups in Nature uncovers a novel mode of inflammatory communication between ILC2s and neurons at mucosal surfaces.
Innate lymphoid cells (ILCs) are an evolutionarily ancient cell population and are highly enriched in mucosal tissues. Recent work has demonstrated that ILCs play a pivotal role in mediating tissue repair as well as coordinating immune responses (Klose and Artis, 2016) . Like helper T cells, ILC subsets exhibit remarkable diversity, allowing them to coordinate immune programs somewhat tailored to viruses or bacteria (groups 1 and 3) and parasites or allergens (group 2). A regulatory T cell-related ILC (ILCreg) was also recently described . Despite their key role in inflammatory processes, ILCs in mice lack receptors capable of recognizing antigen diversity. Instead, ILCs act as selective immune amplifiers, integrating secreted signals from multiple cell types to enhance tissue responses. For example, specialized epithelial cells that monitor the intestinal lumen, termed tuft cells, can augment a type 2 immune response to a worm infection through IL-25 alarmin secretion that activates ILC2s (von Moltke et al., 2016) . These observations raise questions about whether other cell types typically tuned to survey mucosal surfaces could signal to ILCs. Neurons and glia in particular are ideally positioned to respond to changes in the mucosal environment (Veiga-Fernandes and Mucida, 2016) . Prior studies have pointed to a homeostatic (Ibiza et al., 2016) and inflammatory role (Talbot et al., 2015) of nervous system input to ILCs in mucosal tissues, suggesting that this interaction may be a key component of mucosal immunity.
In two recent issues of Nature, work from Cardoso et al., Klose et al., and Wallrapp et al. aimed at defining new signaling pathways capable of controlling mucosal group 2 innate lymphoid cells (ILC2s). To probe modulatory inputs to ILC2s, the three independent research groups sequenced different populations of ILCs in mice. Both bulk (Cardoso et al., 2017; Klose et al., 2017) and single-cell (Wallrapp et al., 2017 ) RNA sequencing of ILC subsets led to the discovery that ILC2s in the lungs and intestine selectively express Nmur1, a receptor for neuromedin U (NMU). Furthermore, expression of Nmur1 was detected in ILCs from human peripheral blood (Cardoso et al., 2017) and intestine samples (Klose et al., 2017) , providing additional relevance to the initial murine results. Subsequent immunofluorescence microscopy analyses in mouse lungs and intestine revealed that ILC2s lie in close proximity to potential NMU+ neuronal processes. NMU is expressed exclusively by neurons and affects diverse physiological processes. For example, NMU has been shown to control smooth muscle function and satiety signals and is thought to modulate eosinophilia following allergen-induced asthma (Moriyama et al., 2006) . Based on these results, the authors hypothesized that ILC2s in mucosal tissues may be capable of responding to NMU.
To better define this potential ILC2-neuron communication, the investigators performed in vitro assays with ILC2s purified from either mouse lungs or small intestine. Addition of NMU peptide to cell cultures resulted in proliferation of ILC2s and significantly increased transcript and protein levels of the cytokines IL-5 and IL-13, which are crucial mediators of type 2 immunity. Intranasal or intraperitoneal administration of NMU peptide also contributed to a large increase in the number of ILC2s in vivo. In contrast to NMU stimulation in cell culture, in vivo NMU stimulation required alarmins IL-25 and IL-33 in order to drive ILC2-specific cytokine production (Cardoso et al., 2017 (Talbot et al., 2015) ; however, these studies lacked genetic models to definitively link homeostatic and type 2 immunity effects. To study ILC2-NMU immune responses in vivo, the researchers used two different type 2 immune response mouse models. While Cardoso et al. and Klose et al. used a model of worm infection, Nippostrongylus brasiliensis, in the lungs and intestine, Wallrapp et al. used a model of airway allergy, house dust mite inoculation, in the lungs. Administering NMU to worm-infected or allergic mice strikingly enhanced their ability to mount an immune response, resulting in reduced worm burden in the gut and lungs or increased lung histopathology with an allergen. These changes in inflammation were mirrored by an increase in ILC2 numbers and type 2 cytokines. In contrast, perturbing NMU or NMUR1 expression hindered worm clearance and attenuated lung inflammation. These results were accompanied by decreases in ILC2 numbers and cytokine production. Finally, Cardoso et al. and Klose et al. found that Nmu expression was significantly increased in the lung and intestine during a worm infection. Through these in vivo inflammation models, the researchers illustrate that an increase in NMU acts through ILC2-specific NMUR1 and is necessary to efficiently mount a type 2 immune response (Figure 1) .
The ability to boost type 2 immune responses holds great therapeutic potential. The discovery of this novel NMU-ILC2 amplification loop adds an important layer in the understanding of ILC modulation and function, but the relevance of this pathway in humans requires further inquiry. Although Cardoso et al. and Klose et al. find that human ILC2s express Nmur1, it is not clear whether ILCs can respond to NMU or if this pathway plays a role in human type 2 immunity. The data also point to increases in inflammation-induced damage as a result of NMU administration in the lungs and suggest a double-edged nature of this inflammatory pathway. Anatomically restricted administration of NMU could be a potential next step toward a feasible clinical application. One avenue to appropriately control NMU release could involve identification of the distinct populations of peripheral neurons that are activated during type 2 inflammation. The recent explosion in opto-and chemogenetic tools provide a potential avenue to take tracing data further, allowing for specific induction of NMU release. The work led by Cardoso et al. ends with intriguing preliminary data suggesting that neuron-specific loss of pathogen or alarmin detection may impair NMU production in vitro and reduce ILC2 activation in vivo. The potential of neurons to directly detect pathogens and/or tissue alarm signals is an exciting and persistent question in the field of neuro-immunology, and future efforts to dissect mucosal innervation and probe the cell populations surveying mucosal surfaces will be critical. Finally, it is possible that ILCs and neurons may have co-evolved complementary signaling pathways, suggesting that additional receptor-ligand interactions remain to be uncovered. The exquisite works of Cardoso et al., Klose et al., and Wallrapp et al. have independently confirmed a truly remarkable and potent mucosal neuro-immune link. Now the question remains: how far can U go?
